Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

摘要: A high incidence of interstitial lung disease (ILD) has been reported in patients with non-small cell cancer (NSCLC) treated gefitinib Japan. We retrospectively analyzed 112 advanced NSCLC who received monotherapy. Univariate and multivariate analyses were used to identify risk factors for gefitinib-related ILD predictive tumor response gefitinib. The was 5.4%, it higher the pre-existing pulmonary fibrosis (33% versus 2%; P < 0.001). results a analysis showed that significant factor (odds ratio: 177, 95% confidence interval: 4.53-6927, = 0.006). rate 33% 98 evaluable women (53% 23%; 0.003), adenocarcinoma (38% 6%; 0.010), never-smokers (63% 18%; 0.001), no history thoracic radiotherapy (39% 13%; 0.015). predictors "no smoking" radiotherapy". Never-smokers had significantly longer survival time than smokers (P 0.007). Although therapy confers clinical benefit on NSCLC, especially women, adenocarcinoma, never-smokers, radiotherapy, also poses ILD, fibrosis. risk-benefit ratio must be carefully considered.